A vaccine platform developed from a synthetic polymeric glyco-adjuvant and reversibly conjugated to an antigen was shown to target dendritic cells leading to cellular and humoral immune response against malaria.
References
Seder, R. et al. Vaccine 33, B40–B43 (2015).
Wilson, D. S. et al. Nat. Mater. https://doi.org/10.1038/s41563-018-0256-5 (2018).
Steinman, R. M. & Banchereau, J. Nature 449, 419–426 (2007).
Lambrecht, B. N., Kool, M., Willart, M. A. M. & Hammad, H. Curr. Opin. Immunol. 21, 23–29 (2011).
Idoyaga, J. et al. Proc. Natl Acad. Sci. USA 108, 2384–2389 (2011).
Burgdorf, S., Kautz, A., Böhnert, V., Knolle, P. A. & Kurts, C. Science 316, 612–616 (2007).
Kashem, S. W., Haniffa, M. & Kaplan, D. H. Annu. Rev. Immunol. 35, 469–499 (2017).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Kooyk, Y. Next-generation malarial vaccines. Nature Mater 18, 94–96 (2019). https://doi.org/10.1038/s41563-018-0267-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41563-018-0267-2
- Springer Nature Limited